Effect of Ocrelizumab on Gray Matter Pathology, Leptomeningeal Inflammation and Cognitive Dysfunction in Multiple Sclerosis

Trial Profile

Effect of Ocrelizumab on Gray Matter Pathology, Leptomeningeal Inflammation and Cognitive Dysfunction in Multiple Sclerosis

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Ocrelizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Dec 2017 Status changed from not yet recruiting to recruiting.
    • 16 Aug 2017 Planned initiation date changed from 31 May 2017 to 1 Sep 2017.
    • 01 May 2017 Planned initiation date changed from 1 Mar 2017 to 31 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top